CIK 0001785345
LABP Landos Biopharma, Inc.
Insider trading from SEC Form 4. Last filing May 23, 2024.
In brief
Landos Biopharma, Inc. (LABP) has 10 SEC Form 4 filings on file from 8 insiders, the latest filed on May 23, 2024. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
Last 90 days
Signals
Open-market buys and sells at Landos Biopharma, Inc., scored.
Transactions
Every row filed, 23 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 23, 2024 | Roger Adsett director | DDisposition to issuer Stock Option (right to buy)derivative | -1,800 | - | - | 0 | May 23, 2024 |
| May 23, 2024 | Alka Batycky director | DDisposition to issuer Stock Option (right to buy)derivative | -3,600 | - | - | 0 | May 23, 2024 |
| May 23, 2024 | Fred Callori director | DDisposition to issuer Stock Option (right to buy)derivative | -1,800 | - | - | 0 | May 23, 2024 |
| May 23, 2024 | Timothy M Mayleben director | DDisposition to issuer Stock Option (right to buy)derivative | -1,800 | - | - | 0 | May 23, 2024 |
| May 23, 2024 | Fabio Cataldi Chief Medical Officer | DDisposition to issuer Restricted Stock Unitderivative | -48,813 | - | - | 0 | May 23, 2024 |
| May 23, 2024 | Gregory Oakes Chief Executive Officer | DDisposition to issuer Restricted Stock Unitderivative | -54,454 | - | - | 0 | May 23, 2024 |
| May 23, 2024 | Christopher Nishan Garabedian director | DDisposition to issuer Stock Option (right to buy)derivative | -1,800 | - | - | 0 | May 23, 2024 |
| May 23, 2024 | Tiago Girao director | DDisposition to issuer Stock Option (right to buy)derivative | -1,800 | - | - | 0 | May 23, 2024 |
| May 23, 2024 | Roger Adsett director | DDisposition to issuer Stock Option (right to buy)derivative | -1,800 | - | - | 0 | May 23, 2024 |
| May 23, 2024 | Timothy M Mayleben director | DDisposition to issuer Stock Option (right to buy)derivative | -1,800 | - | - | 0 | May 23, 2024 |
| May 23, 2024 | Gregory Oakes Chief Executive Officer | DDisposition to issuer Employee Stock Option (right to buy)derivative | -47,529 | - | - | 0 | May 23, 2024 |
| May 23, 2024 | Tiago Girao director | DDisposition to issuer Stock Option (right to buy)derivative | -1,800 | - | - | 0 | May 23, 2024 |
| May 23, 2024 | Christopher Nishan Garabedian director | DDisposition to issuer Stock Option (right to buy)derivative | -1,800 | - | - | 0 | May 23, 2024 |
| May 23, 2024 | Fabio Cataldi Chief Medical Officer | DDisposition to issuer Employee Stock Option (right to buy)derivative | -18,449 | - | - | 0 | May 23, 2024 |
| May 23, 2024 | Fred Callori director | DDisposition to issuer Stock Option (right to buy)derivative | -1,800 | - | - | 0 | May 23, 2024 |
| May 23, 2024 | Christopher Nishan Garabedian director | DDisposition to issuer Stock Option (right to buy)derivative | -1,800 | - | - | 0 | May 23, 2024 |
| May 23, 2024 | Fabio Cataldi Chief Medical Officer | DDisposition to issuer Employee Stock Option (right to buy)derivative | -39,999 | - | - | 0 | May 23, 2024 |
| May 23, 2024 | Tiago Girao director | DDisposition to issuer Stock Option (right to buy)derivative | -1,800 | - | - | 0 | May 23, 2024 |
| May 23, 2024 | Fred Callori director | DDisposition to issuer Stock Option (right to buy)derivative | -1,800 | - | - | 0 | May 23, 2024 |
| May 23, 2024 | Gregory Oakes Chief Executive Officer | DDisposition to issuer Employee Stock Option (right to buy)derivative | -167,724 | - | - | 0 | May 23, 2024 |
| May 23, 2024 | Roger Adsett director | DDisposition to issuer Stock Option (right to buy)derivative | -3,600 | - | - | 0 | May 23, 2024 |
| Feb 29, 2024 | Fabio Cataldi Chief Medical Officer | AGrant or award Restricted Stock Unitderivative | +21,138 | $0.00 | $0 | 21,138 | Mar 4, 2024 |
| Feb 29, 2024 | Gregory Oakes Chief Executive Officer | AGrant or award Restricted Stock Unitderivative | +54,454 | $0.00 | $0 | 54,454 | Mar 4, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Roger Adsettcoo, officer, director
- Alka Batyckydirector
- Fred Calloridirector
- Fabio CataldiChief Medical Officer
- Christopher Nishan Garabediandirector
- Tiago Giraocfo, officer, director
- Timothy M Maylebendirector
- Gregory OakesChief Executive Officer
Questions about LABP
Answered from the filings on this page, as of the latest one.
Are insiders buying LABP?
No. In the last 90 days no insider at Landos Biopharma, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade LABP on the open market?
No open-market trade has been scored at Landos Biopharma, Inc.. The latest Form 4 on file was filed on May 23, 2024 and holds grants, exercises or other rows that are not market trades.
How many insiders file Form 4 at Landos Biopharma, Inc.?
8 people have filed a Form 4 at Landos Biopharma, Inc., among them Roger Adsett (COO and director), Alka Batycky (director), Fred Callori (director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.